Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 172 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Next Generation Sequencing Clear all
Completed Phase 2 Interventional Results available

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

NCT01959490
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
trastuzumab, Pertuzumab, docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, Bevacizumab
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 2, 2026, 9:59 AM EDT
Completed Not applicable Interventional

Next Generation Sequencing Screening for Embryonic Ploidy Status

NCT02032264
View directory record Official record
Conditions
Infertility
Interventions
Comprehensive Chromosome Screening, Morphologically Best
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting No phase listed Observational

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

NCT05234177
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
20
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Bethesda, Maryland + 14 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 2, 2026, 9:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19

NCT04548895
View directory record Official record
Conditions
Covid19, Community-Acquired Respiratory Tract Infection
Interventions
Observational measurement of biometric data. No change to health care provided.
Device
Lead sponsor
Health Stream Analytics, LLC
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pasco, Washington
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 2, 2026, 9:59 AM EDT
Not yet recruiting Phase 3 Interventional

Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:

NCT07458230
View directory record Official record
Conditions
Next Generation Sequencing (NGS), Surgical Site Infection (SSI), Fracture Fixation
Interventions
NGS diagnostic findings
Diagnostic Test
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 84 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
18
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting No phase listed Observational

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

NCT02610439
View directory record Official record
Conditions
Breast Carcinoma, Neuropathy
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2100
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

NCT05199584
View directory record Official record
Conditions
Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions
ENV-101 (taladegib)
Drug
Lead sponsor
Endeavor Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting No phase listed Observational

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

NCT06207032
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Whittier, California • Norwich, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Completed No phase listed Observational

Predicting Disease Progression and/or Recurrence in Cancer

NCT04776837
View directory record Official record
Conditions
Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Esophageal Cancer, Metastatic Cancer, Disease Progression, Survival Analysis
Interventions
Observational Cohort
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting No phase listed Observational

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

NCT04723095
View directory record Official record
Conditions
Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma, Cervical Undifferentiated Carcinoma, Stage I Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8
Interventions
Follow-Up, Medical Chart Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2044
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Completed No phase listed Observational

Use of NGS Cell-free Pathogen Test for Identification of Low Risk Fever & Neutropenia in Pediatric Patients

NCT03530072
View directory record Official record
Conditions
Neutropenia, Fever
Interventions
Karius Test
Diagnostic Test
Lead sponsor
Karius, Inc.
Industry
Eligibility
1 Year to 22 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Avo In R/R And Previously Untreated MCL

NCT04855695
View directory record Official record
Conditions
Mantle Cell Lymphoma, Refractory Lymphoma
Interventions
Acalabrutinib, Venetoclax, Obinutuzumab
Drug
Lead sponsor
Austin I Kim
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Completed Not applicable Interventional Results available

Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections

NCT03846804
View directory record Official record
Conditions
Musculoskeletal Infection, Acute Hematogenous Osteomyelitis, Septic Arthritis, Osteomyelitis, Pyomyositis
Interventions
Karius Test
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
6 Months to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 2, 2026, 9:59 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

NCT04077463
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting Phase 1 Interventional

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

NCT06529822
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
Interventions
Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera assay
Biological · Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
3
States / cities
Orlando, Florida • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting Phase 4 Interventional

NextGen - Clinical Implication of Next Generation Sequencing

NCT05206500
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Antibiotic, Next Gen
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting Not applicable Interventional

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

NCT06896162
View directory record Official record
Conditions
Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions
Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Active, not recruiting No phase listed Observational

Next Generation Pathogen Sequencing for Prediction of Adverse Events

NCT03226158
View directory record Official record
Conditions
Bloodstream Infection
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting No phase listed Observational

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT05178498
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions
Follow-Up, Physical Examination, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting No phase listed Observational

Tempus Small Cell Lung Cancer Observational Study (Sculptor)

NCT05257551
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Alamitos, California • Aurora, Colorado • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Completed Not applicable Interventional

Flourish HEC to Prevent Recurrence of BV

NCT05386147
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)
Device
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rosemont, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnosis and Treatment of Patients With Inborn Errors of Metabolism

NCT00369421
View directory record Official record
Conditions
Arterial Calcification Due to Deficiency of CD73
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 115 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1978
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 9:59 AM EDT
Recruiting Phase 2 Interventional

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

NCT03509961
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
Diagnostic Test · Drug
Lead sponsor
Pediatric Transplantation & Cellular Therapy Consortium
Other
Eligibility
1 Year to 25 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 2, 2026, 9:59 AM EDT
Completed No phase listed Observational

Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse

NCT02679950
View directory record Official record
Conditions
Neoplasms, Germ Cell and Embryonal
Interventions
Next generation genome sequencing
Genetic
Lead sponsor
Nasser Hanna
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 2, 2026, 9:59 AM EDT